Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 417-421

  Anderson, Charles K ^a   Wallace, Shannon ^a   Guiahi, Maryam ^a   Sheeder, Jeanelle ^a   Behbakht, Kian ^a   Spillman, Monique A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Ovarian carcinoma; Risk reduction; Salpingectomy

Indexed keywords

CANCER PREVENTION; DIAGNOSTIC ERROR; GENE MUTATION; HEREDITY; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; OVARIECTOMY; OVARY CARCINOMA; PELVIC SEROUS CANCER; PELVIS CANCER; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UTERINE TUBE;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; PELVIC NEOPLASMS; RISK REDUCTION BEHAVIOR; SALPINGECTOMY;

EID: 84876233553     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182849dba     Document Type: Review

References (47)

1. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44.
2. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
3. Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009;113:391-396.
4. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9.
5. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
6. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: A clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72:367-379.
7. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: Diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797-806.
8. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204:e1-e6.
9. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol. 2004;23:29-34.
10. Mingels MJ, Roelofsen T, van der Laak JA, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012;127:88-93.
11. ACOG. ACOG practice bulletin no. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113:957-966.
12. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol. 2007;8:26-34.
13. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773-1779.
14. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25:3831-3836.
15. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet. 2001;357:1467-1470.
16. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study. J Natl Cancer Inst. 2003;95:1072-1078.
17. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.
18. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927.
19. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol. 2006;7:223-229.
20. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
21. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol. 2008;26: 1331-1337.
22. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.
23. Morrison JH, Brinton RD, Schmidt PJ, et al. Estrogen, menopause, and the aging brain: How basic neuroscience can inform hormone therapy in women. J Neurosci. 2006;26: 10332-10348.
24. Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89:281-287.
25. Chlebowski RT. Breast cancer risk reduction: Strategies for women at increased risk. Annu Rev Med. 2002;53:519-540.
26. Shuster LT, Gostout BS, Grossardt BR, et al. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008;14:111-116.
27. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: Clinical evidence for a window of opportunity. Brain Res. 2011;1379: 188-198.
28. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475-1479.
29. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol. 2005;23:7491-7496.
30. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancerVis it safe?), a randomised comparison: Trial stopped. Lancet. 2004;363:453-455.
31. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15:103-105.
32. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410-419.
33. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res. 2012;5:13.
34. Cibula D, Widschwendter M, Majek O, et al. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum Reprod Update. 2011;17:55-67.
35. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160:613-618.
36. Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009;18:601-610.
37. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw. 2010;8:562-594.
38. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265-271.
39. Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004;10:S5-S9.
40. Peterson HB, Xia Z, Hughes JM, et al. The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of SterilizationWorking Group. N Engl J Med. 1997;336:762-767.
41. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit. 2008;14:CR24-CR31.
42. Sightler SE, Boike GM, Estape RE, et al. Ovarian cancer in women with prior hysterectomy: A 14-year experience at the University of Miami. Obstet Gynecol. 1991;78:681-684.
43. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer. 1993;71:1629-1638.
44. Salvador S, Gilks B, Kobel M, et al. The fallopian tube: Primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009;19:58-64.
45. Westhoff C, Davis A. Tubal sterilization: Focus on the U.S. experience. Fertil Steril. 2000;73:913-922.
46. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at: Http://seer.cancer.gov/faststats. Accessed April, 2012.
47. Dietl J, Wischhusen J, Hausler SF. The post-reproductive Fallopian tube: Better removed? Hum Reprod. 2011;26: 2918-2924.